Similarly, a phase III trial in NSCLC patients with EGFR mutations revealed improved PFS for the combination therapy of bevacizumab and erlotinib versus erlotinib alone, though with a higher incidence of AEs [137]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.